Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.

Autor: Fleishaker DL; Pfizer Inc, 700 Chesterfield Parkway, St, Louis, MO, 63017, and Eastern Point Road, Groton, CT, 06340 USA. dona.l.fleishaker@pfizer.com, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG

Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2012 Jan 17; Vol. 14 (1), pp. R11. Date of Electronic Publication: 2012 Jan 17.